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The cellular microenvironment in follicular lymphoma is of biological and clinical importance. Studies on the clin-
ical significance of non-malignant cell populations have generated conflicting results, which may partly be influ-
enced by poor reproducibility in immunohistochemical marker quantification. In this study, the reproducibility of
manual scoring and automated microscopy based on a tissue microarray of 25 follicular lymphomas as compared
to flow cytometry is evaluated. The agreement between manual scoring and flow cytometry was moderate for
CD3, low for CD4, and moderate to high for CD8, with some laboratories scoring closer to the flow cytometry
results. Agreement in manual quantification across the 7 laboratories was low to moderate for CD3, CD4, CD8
and FOXP3 frequencies, moderate for CD21, low for MIB1 and CD68, and high for CD10. Manual scoring of the
architectural distribution resulted in moderate agreement for CD3, CD4 and CD8, and low agreement for FOXP3
and CD68. Comparing manual scoring to automated microscopy demonstrated that manual scoring increased the
variability in the low and high frequency interval with some laboratories showing a better agreement with auto-
mated scores. Manual scoring reliably identified rare architectural patterns of T-cell infiltrates. Automated
microscopy analyses for T-cell markers by two different instruments were highly reproducible and provided
acceptable agreement with flow cytometry. These validation results provide explanations for the heterogeneous
findings on the prognostic value of the microenvironment in follicular lymphoma. We recommend a more objec-
tive measurement, such as computer-assisted scoring, in future studies of the prognostic impact of microenviron-
ment in follicular lymphoma patients.  
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ABSTRACT
Introduction
Follicular lymphoma (FL) is the second most frequent non-
Hodgkin lymphoma in the western world. FL is generally an
indolent disease with a 7-12 year median survival.1 The sur-
vival distribution is relatively wide and the outcome has
improved over recent years.2 In approximately 20% of the
patients, long-lasting remissions may be achieved,3 while
others die early, often due to transformation to a high-grade
lymphoma.4,5 Therefore, determining factors associated with
response to treatment and survival are particularly important
to guide treatment selection.6 Today, prognostic factors are
limited to clinical prognostic indices, such as the Follicular
Lymphoma International Prognostic Index (FLIPI).7,8
However, the clinical behavior is also influenced by genetic
aberrations present in the tumor cells, by the tumor grade,
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and by immune cell infiltrates in the tumor microenviron-
ment. 
Gene expression analyses have demonstrated that FL
biology may be influenced by the non-malignant tumor
microenvironment,9,10 stimulating numerous subsequent
studies based on immunohistochemical analyses of vari-
ous cellular components in the microenvironment. Such
studies have further explored the prognostic role of specif-
ic T-cell and accessory cell populations, such as helper and
cytotoxic T cells, regulatory T cells, macrophages, follicu-
lar dendritic cells and microvascularity. The results, how-
ever, are often contradictory, with specific cell populations
significantly correlating with poor prognosis in some
series, but with good prognosis or without any significant
impact in others.11 A possible explanation for the dis-
crepant results is patient selection bias, with a wide varia-
tion in age groups and risk factors. It is also likely that spe-
cific types of treatment influence or modify the prognostic
impact of certain parameters in the microenvironment.6,11 
Another possible explanation for the contradictory
results is variation in the immunohistochemical staining
and scoring across laboratories. We have previously
shown that the reproducibility of scoring immunohisto-
chemical stainings is poor and often inadequate for several
frequently reported markers expressed on lymphoma cells
in diffuse large B-cell lymphoma (DLBCL).12 Similar issues
with reproducibility were reported in solid malignancies
for HER2 expression in breast cancer13 and for EGFR in
lung carcinoma.14 
The studies mentioned above for various markers in
DLBCL, and on HER2 and EGFR in carcinomas, focused
on analyzing protein markers expressed by tumor cells. In
contrast, immunohistochemical studies in FL mostly
report on densities and distribution patterns of non-malig-
nant immune cell populations present in the microenvi-
ronment. The reproducibility of scoring such parameters
across laboratories has not yet been studied. Therefore,
we performed a validation study focusing on the repro-
ducibility of scoring cells and cellular distribution patterns
in the tumor microenvironment before launching a large
study on the impact of the tumor microenvironment in FL.
The markers were chosen to be representative of frequent
and less frequent cell populations (CD3 vs. CD8 and
FOXP3), non-malignant lymphoid populations with mem-
branous and nuclear staining patterns (CD3, CD4, CD8 vs.
FOXP3), membranous and nuclear staining patterns on
tumor cells (CD10 and MIB1), stromal cell components
(CD21), and microvessel density (CD34). Importantly,
immunohistochemistry scores (referred to as “manual”
scores) are compared to flow cytometry data for CD3,
CD4 and CD8 available from the same biopsy in all cases.
A computerized system with an automated scanning
microscope and computerized image analysis were also
used for comparison to the manual scoring by patholo-
gists.
Methods
Flow cytometry
A representative portion of the FL lymph node biopsy was
processed by the BC Cancer Agency’s core clinical flow laboratory
and dissociated into a single cell suspension by mincing the tissue
using a sterile scalpel and phosphate buffered saline (Invitrogen
Canada Inc., Burlington, ON, Canada) in a sterile Petri dish. Cells
were counted, then co-stained using 6 panels of antibodies (all
from Beckman Coulter, Fullerton, CA, USA). Information on anti-
body panels is provided in the Online Supplementary Appendix.
Flow cytometry was performed on a Beckman Coulter FC500
flow cytometer.
Tissue microarray construction
Tissue microarrays (TMAs) were prepared at the Dept. of
Pathology of the British Columbia Cancer Agency (BCCA) from
25 representative, newly diagnosed cases of FL and 2 tonsil sam-
ples with adequate archival formalin-fixed and paraffin-embedded
material for which also routine flow cytometry data for CD3, CD4
and CD8 from the same FL lymph nodes were available.
Representative 1.0 mm cores were taken and re-embedded in
duplicate according to standard procedures. Five µm sections were
stained with antibodies to 9 markers (Table 1) according to stan-
dard protocols at the Dept. of Pathology, The Netherlands Cancer
Institute, The Netherlands. 
Criteria and scoring methods for 
immunohistochemistry
Scoring criteria and cut-off points for densities and patterns of
non-malignant cells in FL (Table 2) were based on currently used
methods published by various research groups.15-18 The scoring
method was designed to allow comparison with the flow cytom-
etry data expressed as positive cells for a given marker/total num-
ber of cells analyzed. A “scoring manual” was constructed as an
additional guideline.
The same slide set was rotated among laboratories and inde-
pendently analyzed by 7 pathologists/teams using the scoring
manual as a guideline. The score for each core was recorded sep-
arately on an Excel worksheet. If the core could not be scored, the
reason was recorded (Online Supplementary Table S5). Scores were
reported to a central laboratory for analysis. Further information
on the scoring is provided in the Online Supplementary Appendix.
Additionally, all slides were scored using a computerized system
with an automated scanning microscope and computerized image
analysis (“Ariol Cambridge”) (Ariol SL-50, Genetix Ltd.,
Queensway, New Milton, Hampshire, UK) in combination with
the Multistain assay in the Ariol software for quantification, as
previously described.19 For CD3, CD4 and CD8, the automated
scoring was repeated using a different operator and a different
scanning and image analysis instrument of the same type, scan-
ning microscope Olympus BX61, Ariol SL-50, v.3.4, Genetix Corp.
1998-2009 and the Multistain assay in the Ariol software for quan-
tification (“Ariol Madrid”).20 
Further information on the scoring methods is provided in the
Online Supplementary Appendix.
B. Sander et al.
716 haematologica | 2014; 99(4)
Table 1. Antibodies used for immunohistochemistry.
Target protein               Antibody clone                       Source
CD3                                      CD3                                                 DAKO
CD4                                      4B12                                               Novocastra
CD8                                      C8/144B                                         DAKO
CD10                                    56C6                                               Novocastra
CD21                                    1F8                                                  DAKO
CD34                                    QBEND/10                                    Novocastra
CD68                                    KP1                                                 DAKO
FoxP3                                  236A/E7                                         Abcam
Ki-67                                    MIB1                                              DAKO
DAKO (Glostrup, Denmark); Novocastra (Newcastle upon Tyne, UK); Abcam
(Cambridge, UK).
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Statistical analysis
All information on the statistical analysis is provided in the
Online Supplementary Methods.
Ethical Committee approval
Approval to review, analyze and publish the data in this study
was given by the University of British Columbia–British Columbia
Cancer Agency Research Ethics Board.
Results 
Analysis of CD3, CD4 and CD8 positive cells
Densities of T-cell infiltration by flow cytometry versus
manual or automated microscopy scoring of 
immunohistochemical stainings
Using flow cytometry, CD3 positive (CD3+) T cells
ranged from 7-58% (median 32%), CD4+ T cells ranged
from 5-41% (median 20%) and CD8+ T cells ranged from
2-14% (median 7%) of all viable cells in the sample. Thus
there was a marked variation in the number of T cells and
T-cell subsets, and the values observed are similar to pre-
viously reported results.21
Similar distributions of manual scores for T-cell markers
in the two cores were observed (Figure 1 and Online
Supplementary Tables S1 and S2).  As shown in Table 3 and
Figure 2A, there was significant variation (F-test;
P<0.0001) in the scoring results between the 7 laboratories
with 1-2 laboratories with significantly different scores
from others (Lab 1 scored higher and Lab 5 scored lower
for CD3, Labs 5 and 7 scored lower for CD4, and Lab 1
scored higher and Lab 4 scored lower for CD8, as com-
pared to other laboratories). Agreement among all 7 labo-
ratories was observed in 8-17% of the cases and among all
but one laboratory in 38-46% of the cases (Table 4). The
average pairwise agreement of 54-63% resulted in a low
Validation of FL tumor microenvironment analysis
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Figure 1. The distribution of manual scores of all investigated markers for core 1 and core 2 across the 7 laboratories, excluding the cores not
scored. The color-coded labels for the scoring categories for each marker are explained in the lower part of the figure. Note that the results
obtained in the two different cores are very similar for all markers except CD34.
Table 2. Manual scoring of immunohistochemical markers. 
Immunohistochemical marker                                   Scoring parameters, quantification                                   Scoring parameters architectural
                                                                                                                                                                             patterns
CD3                                                                                             NS*, 0-5%, 6-25%, 26-50%, >50%                                                  NS, intrafollicular, interfollicular, diffuse
CD4                                                                                             NS, 0-5%, 6-25%, 26-50%, >50%                                                    NS, intrafollicular, interfollicular, diffuse
CD8                                                                                             NS, 0-5%, 6-25%, 26-50%, >50%                                                    NS, intrafollicular, interfollicular, diffuse
FOXP3                                                                                        NS, 0-5%, 6-25%, 26-50%                                                                 NS, intrafollicular, interfollicular, diffuse, 
                                                                                                                                                                                                                   perifollicular
CD10 on tumor cells in follicles                                          NS, positive weak, positive strong                                               
MIB1 in follicular areas                                                         NS, 0-5%, 6-25%, 26-50%, >50%                                                    
CD68                                                                                           NS, 0-10%, 11-20%, 21-30%, 30-50%                                              NS, intrafollicular, interfollicular, diffuse
CD21 FDC network in follicles                                                                                                                                                          NS, well developed, partly disrupted but 
                                                                                                                                                                                                                   mostly intact, mostly disrupted, absent
CD34 on microvessels                                                                                                                                                                         NS, dense, moderately dense, sparse
*NS: not scored.
Core 1 Core 2
CD3
CD4
CD8
FoxP3
CD10
MIB1
CD68
CD21
CD34
CD3
CD4
CD8
FoxP3
CD10
MIB1
CD68
CD21
CD34
Label CD3/ CD4/ CD8 CD10 CD68 CD24 CD34
MIB1
0-5% 0-10% Well Dense
developed
6-25% Positive 11-20% Partly Moderatly
weak disrupted dense
26-50% Positive 21-30% Mostly Sparse
strong disrupted
>50% 30-50% Absent
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to moderate reproducibility with free marginal kappa sta-
tistic values of 0.43-0.54 (Table 4 and Figure 3).
A comparison of manual scoring and flow cytometry
(Tables 3 and 5) showed that the agreement on average
was moderate for CD3 (a median of 50% of the core scores
agree with flow cytometry across laboratories), low for
CD4 (a median of 38% of the scores agree), and moderate
to high for CD8 (a median of 71% of the scores agree)
(Table 5) with variation in agreement observed by labora-
tory (Table 3). Thus, while certain laboratories agreed well
with the flow cytometry results (e.g. Labs 4 and 6 for CD3)
other laboratories did not (e.g. Lab 1). Disagreement tend-
ed to occur on the high end with manual scoring overesti-
mating the frequencies of cells in the high range for CD3
and CD4 (Table 3). Specifically, among those misclassified,
on average 70, 87 and 100% of the cases had manual scores
higher than flow for CD3, CD4 and CD8, respectively
(Table 5). As an example, for CD4, 0% of cases fell into the
category of more than 50% by flow cytometry as com-
pared to between 8% to 21% by manual scoring (Table 3).
Thus, the manual scoring on average across laboratories
tended to increase the variability and range of T-cell fre-
quencies compared to flow cytometry. However, higher
levels of agreement were observed for specific laboratories
and markers (e.g. Lab 4 for CD3 and Labs 3, 5 and 6 for
CD8), but no systematic trends were observed.
T-cell frequencies analyzed by an automated scanning
microscope (Ariol SL-50 “Cambridge”) were expressed as
percentages of cells positive out of all cells in the core. For
CD3, CD4 and CD8, the median image score was 48, 30
and 20 for core 1 and 50, 34 and 24 for core 2, respectively
(Figure 4). Comparison with the flow cytometry data
demonstrated a moderate correlation between the results
(Spearman correlation of 0.48, 0.60 and 0.35 for CD3,
CD4 and CD8, respectively) (Figure 2B). The frequencies
of T cells and T-cell subsets were higher by the automated
scanning than by flow cytometry (Table 5), resulting in a
low concordance between the two methods (<0.26).
Comparing manual and image scoring for core 1 result-
ed in low to moderate agreement on average in 38, 61 and
B. Sander et al.
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Figure 2. T-cell frequencies as ana-
lyzed by flow cytometry, image
analysis and manual scoring. 
(A) Quantification of CD3, CD4 and
CD8 by flow cytometry, automated
microscopy and image analysis and
by manual scoring in the 7 laborato-
ries. Note that certain laboratories
scored very different from others,
resulting in high variability. However,
for some markers these laborato-
ries were in better agreement with
flow cytometry and/or image analy-
sis results. (B) Comparison of fre-
quencies of CD3, CD4 and CD8 as
analyzed by image analysis and flow
cytometry. There is moderate corre-
lation (p) but low concordance (c)
between results obtained by the two
methods. (C) Comparison of fre-
quencies of CD3, CD4 and CD8 by
two separate automated micro-
scopes, Ariol “Cambridge” and Ariol
“Madrid” show high correlation
between the two instruments.
Figure 3. Agreement of manual
scoring across labs (A) the pair-
wise agreement and 95% boot-
strap confidence intervals and (B)
the free marginal kappa statistic
and 95% bootstrap confidence
intervals. The cases coded as not
scored are included as this indi-
cates disagreement from the labs
which scored these cases.
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P=0.48
c=0.22
P=0.60
c=0.26
P=0.35
c=0.02
Not scored
1 (0-5%)
2 (5-25%)
3 (26-50%)
>50%
P=0.91
c=0.85
P=0.79
c=0.65
P=0.64
c=0.56
A B
Flow
Image
Lab1
Lab2
Lab3
Lab4
Lab5
Lab6
Lab7
Flow
Image
Lab1
Lab2
Lab3
Lab4
Lab5
Lab6
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Flow
Image
Lab1
Lab2
Lab3
Lab4
Lab5
Lab6
Lab7
Pairwise Agreement Free-marginal kappa
0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0
CD3:C1
CD3:C2
CD4:C1
CD4:C2
CD8:C1
CD8:C2
FOXP3:C1 
FOXP3:C2
CD10:C1
CD10:C2
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CD68:C2
CD21:C1
CD21:C2
CD34:C1
CD34:C2
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CD3:C2
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65% of the cases for CD3, CD4 and CD8, respectively
(Table 5). The disagreement tended to occur in the low
and high manual categories for CD3 with a higher percent
of cases scoring 6-25% and lower percent scoring more
than 50% by manual as compared to image (misclassifica-
tion occurring with image scores higher than manual in
77% of misclassified cases on average), in the high manual
categories for CD4 with a higher percent of cases scored
more than 50% for manual as compared to image (mis-
classification occurring with image scores lower than
manual in 67% of misclassified cases on average) and in
the low manual categories for CD8 with a higher percent
of cases scored in 0-5% for manual as compared to image
(image scores higher than  manual  in 100% of the misclas-
sified cases on average) (Table 5 and Figure 5). Similar
results were obtained for core 2. 
High correlation was observed between the two image
analysis instruments  (Spearman correlation 0.64, 0.79 and
0.91 for CD3, CD4 and CD8, respectively) (Figure 2C).
The concordance was moderate to high with estimates for
core 1 of 0.39 (95%CI: 0.01, 0.69), 0.57 (95%CI: 0.30,
0.75), 0.83 (95%CI: 0.67, 0.92) for CD3, CD4 and CD8,
respectively. For core 2, respectively, the estimated concor-
dance was 0.56 (95%CI: 0.24, 0.77), 0.65 (95%CI: 0.48,
0.78) and 0.85 (95%CI: 0.75, 0.91). 
Architectural patterns of T-cell infiltration
Next we investigated whether manual scoring could
identify common and rare distribution patterns of T-cell
subsets (Table 2). There was a moderate agreement in the
scoring of CD3, CD4 and CD8 architectural patterns
(Table 4). The majority of the cases were scored as inter-
follicular  (Online Supplementary Tables S1 and S2) and,
Validation of FL tumor microenvironment analysis
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Table 3. Comparison of T-cell marker scores from flow cytometry, image analysis and manual scoring (Core 1). 
                        Manual scoring category #                                       Agreement measures               Agreement measures              Misclassification 
                                                                                                          for flow and manual               for image and manual                    measure
Method     NS*        0-5%      6-25%       26-50%          >50%              flow =             flow            image =              image               Flow <        image > 
                                                                                                        manual       within 5%        manual           within 5%        manual (%)     manual                    
(%)            manual (%)              (%)              (%) 
CD3                                                                                                                                                                                                                                                                         
Flow                                 0               35                  52                     13                                                                                                                                                                   
Image                              0                9                   52                     39                                                                                                                                                                   
Lab 1              4                                 13                  17                     67                        30                      30                      32                          55                         100                   33
Lab 2                                                 21                  63                     17                        54                      62                      35                          65                          73                    73
Lab 3                                                 21                  63                     17                        50                      58                      43                          74                          67                    77
Lab 4              8                                 29                  46                     17                        68                      77                      38                          71                          71                    77
Lab 5                               13              29                  46                     13                        46                      52                      43                          61                          38                    92
Lab 6                                                 25                  54                     21                        58                      67                      35                          65                          70                    73
Lab 7              4                                 38                  42                     17                        43                      52                      43                          65                          46                    92
CD4                                                                                                                                                                                                                                                                         
Flow                                 8               58                  33                      0                                                                                                                                                                    
Image                              4               29                  67                      0                                                                                                                                                                    
Lab 1              4                                 29                  46                     21                        30                      61                      73                          82                          88                     0
Lab 2                                                 25                  63                     13                        38                      54                      61                          78                          87                    22
Lab 3              4                                 25                  50                     21                        30                      57                      68                          77                          88                     0
Lab 4             13                                33                  38                     17                        38                      71                      55                          80                          85                    33
Lab 5                               21              33                  38                      8                         42                      62                      43                          61                          50                    77
Lab 6                                                 42                  50                      8                         58                      83                      65                          87                          90                    50
Lab 7              4                                 63                  25                      8                         57                      78                      57                          83                          60                    80
CD8                                                                                                                                                                                                                                                                         
Flow                                25              75                   0                       0                                                                                                                                                                    
Image                              0               75                  17                      8                                                                                                                                                                    
Lab 1              4                                 58                  33                      4                         39                      61                      78                          87                         100                   20
Lab 2                                4               88                   4                       4                         71                      91                      75                          96                         100                  100
Lab 3              4               17              75                                            4                         87                      95                      65                          91                         100                  100
Lab 4              4               63              29                                            4                         57                      70                      17                          43                          10                   100
Lab 5                               17              79                                            4                         71                      95                      62                          83                          71                   100
Lab 6                                8               88                                            4                         79                      95                      71                          92                         100                  100
Lab 7              4               42              50                                            4                         61                      80                      43                          70                          33                   100
# The values represent percentages of scored cases. *NS: not scored.
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therefore, the agreement level indicates that the laborato-
ries consistently identified the interfollicular pattern. The
number of cases with diffuse or intrafollicular patterns
was relatively low, limiting the ability to evaluate agree-
ment for these patterns. However, one case had a predom-
inantly intrafollicular distribution pattern for CD4 and all
scoring laboratories correctly identified this case. 
Densities and distribution of FOXP3 cells, representing
nuclear staining in a sparse T-cell subset
Considerable variation (P<0.001) was observed in the
FOXP3+ scoring across the 7 laboratories with 3 of them
(Labs 4, 6 and 7) scoring a higher percentage of cases as 0-
5% and Lab 1 scoring a higher percentage of cases as 5-
25%, indicating the difficulty distinguishing between
these two categories (Online Supplementary Tables S1, S2
and S3). Agreement among all 7 laboratories was 9%,
among all but one laboratory was 48-52%, and average
pairwise agreement of 61-62% resulting in a low to mod-
erate agreement with free marginal kappa statistic value of
0.48-0.49 (Table 4). In the automated microscopy analysis,
most cores were classified with less than 20% FOXP3+
cells (median 9%, range 1-19% for core 1; median 10%,
range 4-22% for core 2) (Figure 4). Compared with image
analysis, manual scoring misclassified many cases in the
lower range resulting in manual scores being lower with
B. Sander et al.
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Figure 4. Distribution of the image scores of all investigated markers for core 1 and core 2, excluding the cores not scored.
Figure 5. Distribution of manual versus automated microscopy
scores for CD3, CD4 and CD8 in core 1. The automated
microscopy values are represented on the x-axis and the manu-
al score categories on the y-axis. The green boxes represent the
image distribution of the cores within the corresponding cate-
gories to which the cores were manually scored. The gray shad-
ed boxes indicate where the automated microscopy scores
should have been if there was perfect agreement between the
two scoring methods, and thus give us a pictorial view of miss-
classification. As can be seen, there is a discrepancy between
manual scoring and automated microscopy in the low range for
CD3 and CD8 and the higher range for CD3 and CD4. 
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92% of misclassified cases on average (range of 50-100%)
(Figure 6). In addition, a few cores in 1-2 laboratories were
manually scored in the highest category (26-50%) while
no such cores were identified by the automated
microscopy analysis (Figure 6). Thus, the variation
observed with the manual scores was greater than that
observed with the automated microscopy analysis with
misclassification mainly occurring in the lower range.
Low agreement between the laboratories was observed
for scoring the architectural pattern of FOXP3+ cells using
4 categories (Tables 2 and 4).  Since the perifollicular pat-
tern (Figure 7) is claimed to be discriminative as a prognos-
tic marker,22,23 we evaluated agreement for this specific
pattern relative to the three others combined and found
Validation of FL tumor microenvironment analysis
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Table 4. Agreement of manual scores among the laboratories. Agreement based on the free marginal kappa statistic is categorized as low agree-
ment (<0.40), moderate agreement (0.40-0.75) and high agreement (>0.75). 
Core 1 2
Marker All labs All but Pairs of Free-marginal All  labs All but Pairs of Free-marginal Agreement
(%) one lab(%) labs (%) kappa* (%) one lab (%) labs (%) kappa*
CD3 8 38 54 0.43 8 38 56 .45 Low to Moderate
CD4 17 46 60 0.49 8 42 58 .47 Low to Moderate
CD8 8 46 59 0.49 13 46 63 .54 Low to Moderate
FoxP3 9 48 61 0.48 9 52 62 .49 Low to Moderate
CD10 82 95 94 0.91 81 95 94 .91 High
MIB1 0 21 47 0.34 0 17 43 .29 Low
CD68 8 33 45 0.31 4 38 47 .33 Low
CD21 22 39 60 0.50 21 42 60 .50 Moderate
CD34 26 65 70 0.60 36 59 74 .65 Moderate
CD3 Patterns 38 67 73 0.64 33 58 70 .60 Moderate
CD4 Patterns 42 71 77 0.69 33 67 72 .63 Moderate
CD8 Patterns 67 83 86 0.81 58 75 82 .76 Moderate
FoxP3 Patterns 13 43 58 0.48 4 26 52 .39 Low
Peri vs. all others 61 74 83 0.74 48 57 74 .62 Moderate
CD68 Patterns 21 50 64 0.52 17 29 54 .39 Low
* Kappa statistic for CD3, CD4, CD8 is 0.31, 0.38, 0.19 for core 1 and 0.34, 0.38, 0.24 for core 2, respectively.  
Kappa statistic for FOXP3, CD10, MIB1, CD68 is 0.25, 0.83, 0.27, 0.05 for core 1 and 0.26, 0.80,0.23,0.05 for core 2, respectively.
Kappa statistic for CD21, CD34 is 0.40,0.38 for core 1 and 0.40, 0.58 for core 2, respectively.
Kappa statistic for CD3, CD4, CD8 patterns is 0.37, 0.47, 0.44 for core 1 and 0.29, 0.39, 0.30 for core 2. 
Kappa statistic for FOXP3 patterns, perifollicular FOXP3 vs. all other patterns, CD68 patterns is 0.38,0.37,0.40 for core 1 and 0.32, 0.32, 0.24 for core 2.
Figure 6. Distribution of manual versus automated microscopy
scores for FOXP3, CD68 and MIB1 in core 1. The automated
microscopy values are represented on the x-axis and the manual
score categories on the y-axis. The green boxes represent the image
distribution of the cores within the corresponding categories to
which the cores were manually scored. The gray shaded boxes indi-
cate where the automated microscopy scores should have been if
there was perfect agreement between the two scoring methods,
and thus give us a pictorial view of missclassification. Note that the
manual scoring underestimated the frequencies of FOXP3 and
MIB1 in the low range and overestimated the frequencies of MIB1
in the higher range. 
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that the characteristic perifollicular localization of FOXP3
was identified in all scoring laboratories except one, result-
ing in a moderate agreement (Table 4). 
Markers expressed on tumor cells: CD10 and MIB1
analyzed by manual scoring and automated microscopy
Most cores were classified as strongly positive and the
reproducibility of the CD10 scores was high with no dif-
ference between the scoring laboratories from analysis of
variance (P=0.9) and agreement in all laboratories of 81-
82% (free marginal kappa of 0.91) indicating high agree-
ment (Table 4 and Figure 3). For MIB1, the reproducibility
of the manual scoring was suboptimal with no agreement
between all 7 laboratories and 17-21% agreement
between 6 of 7 laboratories, and average pairwise agree-
ment of 43-47%, resulting in low agreement (free-margin-
al kappa of 0.29-0.34) (Table 4 and Figure 3). This result
was influenced by two laboratories which systematically
scored low (ANOVA, P<0.0001). However, these two lab-
oratories were in better agreement with the automated
analysis, while the others had a tendency to overestimate
the variation with a higher percent of scores in the 0-5%
and 26-50% and more than 50% categories. The distribu-
tion of the automated microscopy scores was narrower
than appreciated with the manual scoring (Figure 4), with
a median of 14% and range of 3-35% for core 1 and a
median of 16% and range of 0-38% for core 2. For agree-
ment, the manual scores showed a systematic underesti-
mation of the percentages of MIB1+ cells in the low range
as compared to the automated scores (manual scores in
the 0-5% interval had image values higher than 5%) and
an overestimation in the higher range as reflected by the
fact that 4% of cases were scored by image as more than
26% while 51% on average (range 4-71%) were scored
manually as more than 26% (Figure 6 and Online
Supplementary Table S3). 
Scoring of frequencies and architectural patterns 
of cells present in the microenvironment of follicular
lymphoma
In spite of the fact that the majority of CD68+
macrophage scores were in the lowest category (Figure 1),
there was variation (ANOVA, P<0.0001) among scoring
laboratories with 3 laboratories using at least 3 of the 4
categories and the other laboratories with most cases
scored as 0-10% resulting in low agreement with pairwise
agreement of 45-47% and free marginal kappa of 0.31-
0.33 (Table 4). Automated microscopy analysis showed a
narrow distribution with a median of 11% (range 0-30) for
core 1 and 6% (range 6-20) for core 2 (Figure 4). The agree-
ment of CD68 patterns between laboratories was low
(Table 4).
Stainings of CD21 and CD34 represent a different cate-
gory of markers highlighting the intricate pattern of the
follicular dendritic cell network and the microvessel densi-
ty, respectively. For both of these markers the manual
scoring showed a moderate agreement between laborato-
ries with pairwise agreement of 60-74% and free marginal
kappa statistics of 0.50-0.65 (Table 4). For CD34, the dis-
tribution differed in the two cores with a higher frequency
of scores in the category “sparse” in core 1 compared to
core 2 (Figure 1). 
Discussion
The FL tumor microenvironment contains a variable
proportion of non-malignant cells that contribute to the
B. Sander et al.
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Table 5. Summary statistics for the comparison of flow, image and manual scoring for T-cell densities for core 1. The median percent of cores
and range within each category (as appropriate) is reported. 
Method                                                                Statistic                                          CD3 CD4 CD8
Manual score distribution                      Median percent of cores in each
                                                                          category across labs (range)
                                                                                              0-5%                                               0 (0-13)* 0 (0-21)* 17 (0-63)
                                                                                             6-25%                                             25 (13-38) 33 (25-63) 75 (29-88)
                                                                                            26-50%                                            46 (17-63) 46 (38-63) 0 (0-33)**
                                                                                             >50%                                             17 (13-67) 13 (8-21) 4 (4-4)
Categorized flow scores by                                Percent of cases in 
the manual categories                               0-5%, 6-25%, 26-50% and >50%                          0,35,52,13 8,58,33,0 25,75,0,0
Categorized image scores by                             Percent of cores in 
the manual categories                               0-5%, 6-25%, 26-50% and >50%                           0,9,52,39 4,29,67,0 0,75,17,8
Flow vs.manual                                         Median percent of cores across                                
                                                                                          labs (range)                                                   
                                                                                         Flow=manual                                         50 (30-68) 38 (30-58) 71 (39-87)
                                                                                  Among misclassified:                                           
                                                                                        Flow<manual                                      70 (38-100) 87 (50-90) 100 (10-100)   
                                                                                       Flow>manual                                        30 (0-54) 13 (10-50) 0 (0-90)
Image vs.manual                                       Median percent of cores across                                
                                                                                          labs (range)
                                                                                    Image=manual                                    38 (32-43) 61 (43-73) 65 (17-78)***
                                                                                 Among missclassified:
                                                                                    Image<manual                                     23 (8-67) 67 (10-100) 0 (0-80)
                                                                                    Image>manual                                    77 (33-92) 33 (0-80) 100 (20-100)
*1 lab scored 13% of subjects in 0-5% for CD3, 21% of cases in 0-5% for CD4; **2 labs scored subjects in the 25-50% category for CD8. One lab scored 4% and the other 33%; ***In
5 of 7 labs the manual=image in 62-78% of the patients.
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tumor cell survival and are important contributors to FL
biology.24-31 Gene expression studies have demonstrated
that patient survival, risk for transformation and response
to therapy are associated with activation of genes reflect-
ing non-malignant cell content and activation, rather than
genes expressed by the tumor cells.9,10,32 It is hypothesized
that the frequency and distribution of non-malignant cells
can in part serve as surrogate markers for the clinically rel-
evant gene expression signatures. This issue has recently
been the focus of numerous immunohistochemical stud-
ies, including evaluating markers for T-helper, cytotoxic
and regulatory cell subsets,17-21,23,33-35 for stromal cells includ-
ing macrophages, mast cells and dendritic cells,15,20,33,36-39
and for endothelial cells assessing microvessel density.40-42
The results of these studies are often contradictory, which
in part can be explained by the small number of patients
and variations in patient selection and treatment proto-
col.11,43 Another potential reason is the scoring repro-
ducibility of the immunohistochemical markers. It could
well be that evaluating immunohistochemical markers by
manual scoring are reproducible within a study where
scoring is carried out by one individual but is not repro-
ducible over a series of studies where other individuals
score other lymphoma cohorts. In addition, the manual
scoring may be more reproducible once a cut-off point of
clinical relevance based on a larger series of patients has
been established. However, in the development of prog-
nostic and/or predictive markers, which often have the
aim of determining the optimal cut-off point to separate
populations into low or high risk for failure, these markers
are scored in 4-5 categories for most markers. The data in
this study show that with 4-5 categories, the manual scor-
ing agreement is low to moderate.  Therefore, in the
development of prognostic and/or predictive markers (and
as stratification for randomized clinical trials) it is impor-
tant to centralize and standardize marker scoring, or con-
sider alternative approaches to manual scoring, to mini-
mize the variation and increase the power. Once a cut-off
point has been established, it is likely that the manual
scoring agreement will increase across scoring laborato-
ries. The main purpose of this study was to investigate the
feasibility and reproducibility of scoring common FL
microenvironment markers by comparing manual scoring,
automated microscopy and, for T-cell markers, also flow
cytometry. We focused on quantification and architectural
localization of cell types considered to be important for FL
biology and outcome. 
The main conclusions from this study are: 1) T-cell fre-
quencies are highly variable in the lymphoma tissue and
the reproducibility of manual quantification of T cells is
low to moderate; 2) T-cell frequencies as analyzed by flow
cytometry and automated microscopy show moderate
agreement but image analysis overestimates frequencies;
3) for many markers, manual scoring increases the vari-
ability in the low and high frequency interval as compared
to automated microscopy; 4) automated microscopy
analyses for T-cell markers by two different instruments
shows a high degree of correlation; 5) manual scoring can
readily identify rare architectural patterns of T-cell infil-
trates in FL tissue.
T-cell frequencies measured by flow cytometry have
previously been suggested to predict outcome in FL.21,34 In
the present study, we used flow cytometry data for com-
parison with T-cell frequencies obtained by manual and
automated scoring of immunohistochemistry. Flow
cytometry was considered to be the “gold standard” since
it measures and quantifies a high number of cells as single
events and since multiple antigens and CD markers are
used to define a population resulting in high accuracy.44
Flow cytometry is thus a very reliable and quantitative
method for comparing and enumerating frequencies of
numerous and rare cell populations and it can be standard-
ized between laboratories. Flow cytometry can also be
used for detecting intracellular markers, such as BCL2 and
FOXP3, in combination with surface markers, allowing
detailed information on cell subsets to be gathered. The
major disadvantages with this method is that it requires
fresh tissue and does not provide information on the cel-
lular localization, which is of relevance in FL. Furthermore,
in case of fibrosis, or when tumor cells are large and frag-
ile, the cell preparation used for flow cytometry might not
fully represent the cell composition in the tissue. 
A comparison of flow cytometry with image analysis
showed there was a moderate correlation between CD3,
CD4 and CD8 positive T-cell frequencies similar to previ-
ously published results.20 However, both in the present
study and in the study by Wahlin et al. examining T cells
in FL,20 image analysis resulted in higher values for the T-
cell markers compared to flow cytometry, resulting in a
low concordance between the measurements. One possi-
ble explanation for this difference could be cell loss during
preparation of the single cell suspension used for flow
cytometry,44 although this is less likely since preferentially
large cells are lost. Another possibility for the discrepancy
between flow cytometry and image analysis is the pres-
ence of incomplete cells in the tissue sections. It could also
be a “calibration effect” caused by a lower detection
threshold in the image analysis. The low concordance
between flow cytometry and image analysis does not, in
our opinion, rule out using image analysis to reduce scor-
ing variability and to obtain objective quantification since
the effects will be similar across all cases. An advantage in
using automated microscopy or flow cytometry compared
to manual scoring is that quantification is in a continuous
Validation of FL tumor microenvironment analysis
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Figure 7. Perifollicular distribution of FOXP3 positive T cells.
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scale rather than a categorical measurement, providing
more information when evaluating biologically relevant
cut-off points.
For several markers, the manual scoring overestimated
the variation in cell frequencies as compared to flow
cytometry and automated microscopy. On the other hand,
while the variation across laboratories was considerable,
certain laboratories agreed well with each other and with
flow cytometry results. However, this was not consistent
but differed between markers and laboratories, with no
laboratory identified as uniformly reliable.  Studies using
immunohistochemical scoring should be carefully validat-
ed by flow cytometry or image analysis to ensure repro-
ducibility.
The analysis evaluating the reproducibility of T-cell
marker quantification using two separate automated
microscopes in combination with image analysis per-
formed by 2 different instrument operators, showed a high
correlation in scoring CD3, CD4 and CD8 densities. These
results suggest that it is possible to reproducibly score T-
cell markers in FL using image analysis. Image scoring also
enumerates cells as actual values, an obvious advantage
over manual scoring according to category. The frequency
and localization of FOXP3+ Treg cells has been associated
with clinical behavior in FL.20,22,23 For CD4+ T cells, one
study has suggested that a high number of intrafollicular
CD4+ cells is associated with a poor prognosis.20 In the
present validation study, certain architectural patterns were
highly reproducible, such as localization of CD8+ T cells,
while agreement was moderate for localization of CD3+
and CD4+ T cells, as well of CD68+ macrophages.
Importantly, manual scoring did well when it came to rec-
ognizing rare patterns, as exemplified by the perifollicular
localization of FOXP3+ regulatory T cells and intrafollicular
localization of CD4 positive T cells.
This validation study provides explanations for the het-
erogeneous results of various reports in the literature on
the prognostic value of the microenvironment in FL. Based
on these results, we recommend refraining from manual
scoring for research purposes in this field unless careful
validation by other methods is carried out, and recom-
mend the use of a more objective measurement, such as
computer-assisted scoring. 
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